Levitt Oncology Associates was founded by Mark L. Levitt MD PhD to bring a rare combination of deep scientific expertise and pharmaceutical industry leadership to companies developing oncology assets.
Levitt Oncology Associates, Ltd. provides consultative services in oncology to the pharmaceutical industry, serving biotech start-ups, small biopharma, and Big Pharma. LOA specializes in clinical development, business development, scientific and clinical evaluation, and strategy — within the framework of a deep background in all aspects of pharmaceutical development.
While serving companies around the world, LOA has developed a specialty niche in small Israeli biotech and biopharma, and in addition to consulting services, performs Search and Evaluation functions within the vibrant Israeli biotechnology sector.
The CEO, Dr. Mark L. Levitt MD PhD, brings over two decades of experience in the Israeli academic and biotech/biopharma industries, combined with 11 years as a Key Opinion Leader in Lung Cancer in the US and as a leading translational, basic, and clinical scientist in that field.
His approach is grounded in a simple belief: that combining clinical insight with basic science creates a strategic advantage no purely commercial consultant can replicate. Clients come to LOA not for generic advice, but for the kind of judgment that only comes from having done the work — at the bench, in the clinic, and in the boardroom.